SG11201703313SA - Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production - Google Patents
Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their productionInfo
- Publication number
- SG11201703313SA SG11201703313SA SG11201703313SA SG11201703313SA SG11201703313SA SG 11201703313S A SG11201703313S A SG 11201703313SA SG 11201703313S A SG11201703313S A SG 11201703313SA SG 11201703313S A SG11201703313S A SG 11201703313SA SG 11201703313S A SG11201703313S A SG 11201703313SA
- Authority
- SG
- Singapore
- Prior art keywords
- production
- methods
- dimeric immunoglobulins
- cell retargeting
- hetero
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073738 WO2015063339A1 (en) | 2013-11-04 | 2014-11-04 | Production of t cell retargeting hetero-dimeric immunoglobulins |
| EP15167034 | 2015-05-08 | ||
| PCT/EP2015/075628 WO2016071355A1 (en) | 2014-11-04 | 2015-11-03 | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703313SA true SG11201703313SA (en) | 2017-05-30 |
Family
ID=53059011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703313SA SG11201703313SA (en) | 2014-11-04 | 2015-11-03 | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3215541A1 (en) |
| JP (3) | JP2018501297A (en) |
| KR (1) | KR20170078831A (en) |
| CN (1) | CN107207596A (en) |
| AU (1) | AU2015341884B2 (en) |
| BR (1) | BR112017009263A2 (en) |
| CA (1) | CA2965745C (en) |
| CL (1) | CL2017001090A1 (en) |
| CO (1) | CO2017005240A2 (en) |
| EA (1) | EA039658B1 (en) |
| HK (1) | HK1244014A1 (en) |
| IL (1) | IL251848A0 (en) |
| MA (1) | MA40894A (en) |
| MX (1) | MX2017005814A (en) |
| MY (1) | MY186929A (en) |
| NZ (1) | NZ732019A (en) |
| PE (1) | PE20171041A1 (en) |
| PH (1) | PH12017500819A1 (en) |
| SG (1) | SG11201703313SA (en) |
| WO (1) | WO2016071355A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| LT2943511T (en) | 2013-01-14 | 2019-11-11 | Xencor Inc | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3024851B1 (en) | 2013-07-25 | 2018-05-09 | CytomX Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| EP3066133A1 (en) | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| KR102327996B1 (en) | 2014-03-28 | 2021-11-17 | 젠코어 인코포레이티드 | Bispecific antibodies that bind to cd38 and cd3 |
| AU2015292406B2 (en) * | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN107207610B (en) | 2014-11-26 | 2022-09-09 | 森科股份有限公司 | Heterodimeric antibodies that bind CD3 and tumor antigens |
| JP2017536830A (en) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Heterodimeric antibodies that bind to CD3 and CD38 |
| TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for flt3 and cd3 |
| TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for msln and cd3 |
| KR20180085800A (en) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | CD3 and heterodimeric antibodies that bind to PSMA |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| KR20230054508A (en) | 2016-06-14 | 2023-04-24 | 젠코어 인코포레이티드 | Bispecific checkpoint inhibitor antibodies |
| AU2018259039A1 (en) * | 2017-04-24 | 2019-11-07 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of EGFR positive cancers |
| MA49250A (en) | 2017-06-05 | 2021-04-14 | Numab Therapeutics AG | NEW ANTI-CD3 ANTIBODIES |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| US11780930B2 (en) | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| KR20200021068A (en) * | 2017-06-08 | 2020-02-27 | 블랙 벨트 테라퓨틱스 리미티드 | CD38 Modified Antibodies |
| ES2911243T3 (en) * | 2017-08-10 | 2022-05-18 | Grifols Diagnostic Solutions Inc | Compositions, methods and/or kits comprising a recombinant extracellular domain of human cd38 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
| EP3668543A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 antibody |
| KR20200064096A (en) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | Antibodies, activatable antibodies, bispecific antibodies and bispecific activatable antibodies and methods of using them |
| CN112955220A (en) * | 2018-09-25 | 2021-06-11 | 伊克诺斯科学公司 | Antibody quantification in biological samples |
| KR102353568B1 (en) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability |
| AU2020211728A1 (en) * | 2019-01-23 | 2021-08-12 | Encefa | CD31 competitors and uses thereof |
| WO2020182984A2 (en) * | 2019-03-13 | 2020-09-17 | Ichnos Sciences SA | Non-consensus glycosylation of bispecific antibodies |
| US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
| CN110551222B (en) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | Novel bifunctional antibody and application thereof |
| CN113015749B (en) * | 2019-09-30 | 2022-01-21 | 和铂医药(苏州)有限公司 | Antibodies targeting CD3, bispecific antibodies, and uses thereof |
| CN113493519B (en) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CN115916824A (en) * | 2020-06-17 | 2023-04-04 | Y-单克隆抗体制药有限公司 | CD38 antibodies for the treatment of human diseases |
| KR20230166150A (en) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | Anti-cd28 compositions |
| JP2024509274A (en) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Heterodimeric antibody that binds to CD3 and GPC3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140066259A (en) * | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | Anti-cd38 human antibodies and uses therefor |
| CA2602375C (en) * | 2005-03-23 | 2018-07-24 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| LT2860192T (en) * | 2005-10-12 | 2017-12-11 | Morphosys Ag | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2975051B1 (en) * | 2009-06-26 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| KR102103093B1 (en) * | 2009-12-25 | 2020-04-21 | 추가이 세이야쿠 가부시키가이샤 | Polypeptide modification method for purifying polypeptide multimers |
| SI2580243T1 (en) * | 2010-06-09 | 2020-02-28 | Genmab A/S | Antibodies against human cd38 |
| JOP20210044A1 (en) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
| EA201791693A1 (en) * | 2011-03-25 | 2018-05-31 | Гленмарк Фармасьютикалс С.А. | HETERODIMERNY IMMUNOHLOBULINS |
| EP2900696A1 (en) * | 2012-09-25 | 2015-08-05 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| US9486547B2 (en) * | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| EP3066133A1 (en) * | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/en unknown
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/en unknown
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/en active Active
- 2015-11-03 EA EA201790961A patent/EA039658B1/en unknown
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/en unknown
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/en active Pending
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/en active Search and Examination
- 2015-11-03 KR KR1020177015252A patent/KR20170078831A/en not_active Application Discontinuation
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/en active Application Filing
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/en not_active Withdrawn
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/en active Pending
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/en unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/en unknown
-
2018
- 2018-03-12 HK HK18103440.0A patent/HK1244014A1/en unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/en active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021184722A (en) | 2021-12-09 |
| MA40894A (en) | 2017-09-12 |
| PH12017500819A1 (en) | 2017-10-02 |
| JP2019214582A (en) | 2019-12-19 |
| CN107207596A (en) | 2017-09-26 |
| NZ732019A (en) | 2022-07-29 |
| PE20171041A1 (en) | 2017-07-19 |
| CO2017005240A2 (en) | 2017-10-31 |
| JP2018501297A (en) | 2018-01-18 |
| KR20170078831A (en) | 2017-07-07 |
| JP7403505B2 (en) | 2023-12-22 |
| BR112017009263A2 (en) | 2018-01-30 |
| MY186929A (en) | 2021-08-26 |
| AU2015341884A1 (en) | 2017-06-08 |
| MX2017005814A (en) | 2017-08-02 |
| EA039658B1 (en) | 2022-02-22 |
| CA2965745A1 (en) | 2016-05-12 |
| WO2016071355A1 (en) | 2016-05-12 |
| AU2015341884B2 (en) | 2020-09-17 |
| EA201790961A1 (en) | 2017-10-31 |
| EP3215541A1 (en) | 2017-09-13 |
| IL251848A0 (en) | 2017-06-29 |
| CL2017001090A1 (en) | 2018-01-05 |
| HK1244014A1 (en) | 2018-07-27 |
| CA2965745C (en) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244014A1 (en) | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
| IL286835A (en) | Bispecific tetravalent antibodies and methods of makiing and using thereof | |
| HK1252413A1 (en) | Method of culturing akkermansia | |
| IL253149A0 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| ZA201603433B (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| IL248007A0 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| IL257411A (en) | Enhanced production of immunoglobulins | |
| SG11201606575TA (en) | Method of producing polyethylene and polyethylene thereof | |
| HK1251969A1 (en) | Anti-her2 antibodies and methods of use | |
| HK1251580B (en) | Process of manufacture of annexin v | |
| IL248697A0 (en) | Methods of purifying antibodies | |
| IL250451A0 (en) | Anti-vasa antibodies, and methods of production and use thereof | |
| EP3140392C0 (en) | Production of heteromultimeric proteins using mammalian cells | |
| ZA201700525B (en) | Method of synthetic fuel gas production | |
| GB201608060D0 (en) | Method of culturing T cells | |
| IL252712A0 (en) | Method of protein manufacture | |
| SG11201609269TA (en) | Method of culturing cells | |
| GB201411430D0 (en) | Method of producing metallic tanralum | |
| PT3194599T (en) | Method for production of modified cells exprining hox and modified cells obtained by the method |